October 2025
Galenica Group
Strong sales growth in the first 9 months of 2025
+4.7%
2'865
3'000
+5.0%
2'362
2'480
+5.0%
1'243
1'304
Galenica Group Products & Care Logistics & IT
Galenica Group
Sales growth supported by both segments
Net sales (in million CHF) | 09/2025 | 09/2024 | change |
Local Pharmacies | 1'039 | 989 | +5.1% |
Pharmacies at Home | 58 | 57 | +1.3% |
Retail (B2C) | 1'097 | 1'046 | +4.9% |
Products & Brands | 142 | 142 | +0.2% |
Services for Professionals | 72 | 62 | +15.9% |
Professionals (B2B) | 214 | 204 | +5.0% |
Products & Care | 1'304 | 1'243 | +5.0% |
Wholesale | 2'375 | 2'263 | +5.0% |
Logistics & IT Services | 124 | 117 | +6.4% |
Logistics & IT | 2'480 | 2'362 | +5.0% |
Corporate and eliminations | -785 | -740 | |
Galenica Group | 3'000 | 2'865 | +4.7% |
Retail B2C
Strong sales growth with prescription medicines
Net sales (in million CHF)+4.9%
57
1'039
989
58
1'046 1'097
09/2024 09/2025
+1.3%
+5.1%
Portfolio of local pharmacies expanded by 5 locations: expansion impact1 of +1.7%
Generics substitution rate remains with 77.7% at high level (79.2% at Dec 2024).
The effect of net expansion is calculated only including point of sales without a full year period comparison (acquisitions, openings and closure of pharmacies)
Products & Brands
Solid growth in the Swiss market
Net sales (in million CHF)+0.2%
142
114
109
28
33
-14.3%
+4.6%
Swiss market:
− Growth due to expansion of1 +9.7%
− Organic growth CH of -5.1%
− Growth of CH market sales2 -0.4%
− Market share2 of 10.7%
09/2024 09/2025
Expansion impact related new licence agreements in Jan. 2025, the effect of net expansion is calculated only including business activities without a full year period comparison (acquisitions and new license agreements)
Product sales to end customers of Verfora, Spagyros and Padma products (like-for-like, streetprices), IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, Consumer Health market September 2025 YTD
Services for professionals
Strong sales growth due to expansion effects
Net sales (in million CHF)+15.9%
72
− Consistent, pleasing growth with services for homecare organizations and nursing homes, negatively impacted by a decline in Winconcept sales
62
− Growth due to expansion into diagnostics field of 12.6%
09/2024 09/2025
Wholesale
Growth in line with market development
Net sales (in million CHF)+5.0%
2'375
2'263
137
133
1'473
1'553
657
686
+4.4%
+5.4%
Further market share gains in physicians segment
+2.8%
09/2024 09/2025
Logistics & IT Services
Sales growth driven by internal IT services
Net sales (in million CHF)-0.1%
55
55
61
69
+6.4%
117 124
+12.2%
Modest growth continues in IT services and pre-wholesale distribution
09/2024 09/2025
Total market growth
CHF 5,930.2 million (+5.1%)
148.0 million packs (+0.2%)
CHF 1,456.0 million (+5.5%)
11.5 million packs (-1.3%)
Drugstores
24.6%
43.1%
Local Pharmacies
CHF 45.9 million (-4.9%)
4.3 million packs (-6.5%)
0.8%
CHF 2,558.0 million (+5.4%)
97.5 million packs (+0.9%)
CHF 1,578.5 million (+4.2%)
33.5 million packs (-0.3%)
26.6%
4.9%
CHF 291.6 million (+8.2%)
1.3 million packs (-3.6%)
Swiss pharmaceutical market
Market YTD above last year despite one sales day less
in million CHF
750
730
710
690
670
650
630
610
590
570
550
530
510
490
470
450
Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez
Consumer healthcare market September 2025 YTD
2.8%
12.7%
19.8%
64.6%
Total market
CHF 1,930.1 million
-0.4%
-0.3%
-1.4%
+0.9%
-1.6%
Non-medication segment
-0.6%Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices
© IQVIA - Consumer Health market September 2025 YTD
Financial guidance update
Net Sales
4-6%
raised due to acquisition of Labor Team
Dividend
at least at previous year's level
EBIT1
10-12%
adjusted due to one-off effect of
CHF 5.4 million and acquisition of Labor Team
1 Excluding effects of IAS 19 and IFRS 16, see chapter "Alternative performance measures" of the Half year report 2025 , and excluding PPA-related amortization from Labor Team acquisition.
Disclaimer
Disclaimer Galenica
Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward- looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted develop-ments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.
Disclaimer IQVIA © 2025, IQVIA AG
All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as "patient", "doctor", "medical practice", "prescriber", or "pharmacy" do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).
IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.